[go: up one dir, main page]

WO2009064151A1 - Procédé d'obtention d'un extrait sec de galphimia glauca, compositions pharmaceutiques comprenant ledit extrait et utilisation des compositions dans le traitement contre l'anxiété - Google Patents

Procédé d'obtention d'un extrait sec de galphimia glauca, compositions pharmaceutiques comprenant ledit extrait et utilisation des compositions dans le traitement contre l'anxiété Download PDF

Info

Publication number
WO2009064151A1
WO2009064151A1 PCT/MX2007/000135 MX2007000135W WO2009064151A1 WO 2009064151 A1 WO2009064151 A1 WO 2009064151A1 MX 2007000135 W MX2007000135 W MX 2007000135W WO 2009064151 A1 WO2009064151 A1 WO 2009064151A1
Authority
WO
WIPO (PCT)
Prior art keywords
dry extract
obtaining
extract
galphimia glauca
galphimia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/MX2007/000135
Other languages
English (en)
Spanish (es)
Inventor
Jaime Tortoriello Garcia
Armando Herrera Arellano
Alejandro ZAMILPA ÁLVAREZ
Jesús Enrique JIMÉNEZ FERRER
Maribel Lucila Herrera Ruiz
Maira Estrella Huerta Reyes
Manasés GONZÁLEZ CORTAZAR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to PCT/MX2007/000135 priority Critical patent/WO2009064151A1/fr
Publication of WO2009064151A1 publication Critical patent/WO2009064151A1/fr
Priority to MX2009007792A priority patent/MX2009007792A/es
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Definitions

  • the present invention relates to a pharmaceutical formulation comprising a dry extract of the plant species Galphimia glauca (Malpighiaceae) where said extract is obtained with a process that includes solvents of different polarity. Said formulation is used for the treatment, cure and prevention of anxiety in all its pathological forms.
  • the pharmaceutical formulation, object of the present invention provides a solution for the treatment of anxiety since said formulation comprises a dry extract with a higher concentration of active compounds that produces a greater anxiolytic effect, which allows pharmaceutical presentations smaller than those proposed in the state of the art by capsule or dragee, which are more effective and accessible for use by patients.
  • These pharmaceutical presentations include capsules, dragees, tablets, which can be made with techniques conventional manufacturing Pharmaceutical
  • Galphimins A, B, C, D, E, F, G, H, I and J have been isolated as natural products of the methanolic extract of G. glauca mainly (González-Cortázar M, Tortoriello J, Alvarez L. Nor-secofriedelanes as spasmolytics, advances os structure-activity relationships, Planta Med.
  • Galphimina-E greater than or equal to Galphimina-B
  • Galphimina-B much greater than Galphimina-A
  • Herrera-Ruiz M Jiménez-Ferrer JE, DE Lima TCM, Aviles-Montes D , Pérez- Garcia D, González-Cortázar M, Tortoriello J. Anxiolytic and antidepressant-like activity of a standardized extract from Galphimia glauca.
  • Herrera-Ruiz M González M, Jiménez E, Zamilpa A , Alvarez L, Ram ⁇ rez G, Tortoriello J.
  • the treatment to be evaluated consisted of capsules with dry aqueous extract of G. glauca standardized exclusively in its Galphimina-B content (Herrera-Arellano A, Jiménez-Ferrer E, Zamilpa A, Morales-Valdéz M, Garc ⁇ a-Valencia Stephan E, Tortoriello J. Efficacy and Tolerability of a standardized herbal product from Galphimia glauca on generalized anxiety disorder A randomized, double-blind clinical trial controlled with Lorazepam. Planta Medica 2007; 73: 713-717). It was shown that after 4 weeks of treatment with the aqueous dry extract of G.
  • Patent application MX19990004189 proposes a medicament comprising an extract of G. glauca for the treatment of conditions that involve glutamatergic and / or dopaminergic hyperactivity.
  • the medicine proposed in said application has disadvantages, since said extract is only characterized in its chemical composition by the presence of the compound called Galphimine-B.
  • Patent application MX20060008508 claims a pharmaceutical composition comprising at least one of the compounds known as Galphimina-F and Galphimina-B for the treatment of a disease with a spasmogenic dysfunctional condition, as well as for The treatment of an anxiogenic condition.
  • said pharmaceutical composition differs substantially from the present invention, because the pharmaceutical composition uses only pure compounds and therefore involves a chemical-pharmaceutical type drug.
  • the present invention relates to a pharmaceutical composition made from a dry extract that involves an herbal medicine, and therefore, are drugs of a completely different nature.
  • the pharmaceutical composition made from pure compounds presents another disadvantage, since it involves exhaustive purification processes with a high economic cost due to the use of a more sophisticated infrastructure.
  • the present invention relates to a pharmaceutical formulation comprising a dry extract of the plant species Galphimia glauca (Malpighiaceae), where the extract has a controlled concentration and much higher than previously reported of the active ingredients Galphimina-B, Galphimina-A and Galphimina-E (Herrera-Ruiz M, Jiménez-Ferrer JE, DE Lima TCM, Aviles-Montes D, Pérez-Garcia D, González-Cortázar M, Tortoriello J. Anxiolytic and antidepressant-like activity of a standardized extract frora Galphimia glauca Phytomedicine
  • Said formulation proposes a notable improvement with respect to the anxiolytic effect shown by other extracts previously disclosed in the state of the art as illustrated in the examples of the present application, and further proposes, oral administration of a lower dose of dry extract of G Glauca, which may produce it in different presentations more accessible and comfortable for use by patients and also achieve a better anxiolytic effect.
  • the registered side effects are much lower than those of the drugs currently used in anti-anxiety therapy, since only excessive sedation It was the most common effect.
  • the aqueous extract of G. glauca begins its therapeutic effect from the first week of administration, unlike the more recent anxiolytics, such as azapirones and serotonin reuptake inhibitors, whose effect is observed from the fourth week onwards. of treatment.
  • the invention also relates to a method for the preparation of said dry extract, which is obtained by a method of extraction other than extracts already known in the state of the art (aqueous, hydroalcoholic and methanolic) because the method of extraction of the present invention, it is modified in its number of passages and solvents used, since it comprises successive extractions with different organic solvents and mixtures thereof, as well as bipartitions (liquid-liquid separations).
  • a method of extraction other than extracts already known in the state of the art (aqueous, hydroalcoholic and methanolic) because the method of extraction of the present invention, it is modified in its number of passages and solvents used, since it comprises successive extractions with different organic solvents and mixtures thereof, as well as bipartitions (liquid-liquid separations).
  • the invention relates to the use of said extract for the manufacture of pharmaceutical formulations in different dosage forms suitable for oral administration which are indicated for the treatment of anxiety.
  • capsules comprising the pharmaceutical formulation of G. glauca are proposed, which administered in patients reduces anxiety from the first week of treatment, and after 4 weeks of treatment significantly reduces anxiety.
  • a dragee is proposed, which is coated and comprises the formulation of G. glauca, which administered in patients reduces anxiety from the first week of treatment, and after 4 weeks of Treatment significantly reduces anxiety.
  • a tablet which comprises the formulation of G. glauca, which administered to patients reduces anxiety from the first week of treatment, and after 4 weeks of treatment significantly reduces the anxiety.
  • Figure 1 shows the chromatographic profile of the dry extract of G. glauca object of the invention and shows the retention times of the active ingredients called Galphiminas A, B and E (GA, GB and GE, respectively), as well as of the quercetin used as a reference.
  • Galphiminas A, B and E G, GB and GE, respectively
  • Figure 2 shows the anxiolytic activity of the aqueous (Aq), hydroalcoholic (HAq) extracts and the extract object of the invention (Ext inv) obtained from G. glauca in the model Behavioral cross-shaped maze (plus mazé). Data are shown as percentage of entries to open arms ( ⁇ ) and percentage of time over open arms (a). Diazepam (DZP) is used as a positive control and 1% carboxymethyl cellulose (eme) as a vehicle.
  • Figure 3 compares the spontaneous motor activity of the aqueous (Aq), hydroalcoholic (HAq) extracts and the extract object of the invention (Ext inv) of G. glauca in the open-field behavioral model. The data are shown as total number of crosses ( ⁇ ) and number of times of stretching (m). Diazepam (DZP) is used as a positive control and 1% carboxymethyl cellulose (eme) as a vehicle.
  • the pharmaceutical form according to the pharmaceutical formulation object of the present invention is particularly available for oral administration.
  • the dosage forms according to the pharmaceutical formulation object of the present invention can be prepared by conventional manufacturing techniques and methods, among which we can mention:
  • the extract of G. glauca concerning the pharmaceutical formulation object of the present invention, can be mixed with the excipients that allow the proper drying process of the extract either by a spray drying process with hot air or lyophilization. .
  • the dried extract thus obtained is pulverized.
  • the powder has the characteristics of fluidity to be encapsulated in the required dose and hygroscopicity that keeps the pharmaceutical form.
  • the G. glauca extract concerning the pharmaceutical formulation object of the present invention, can be mixed with the excipients that allow the proper drying process of the extract either by a spray drying process with hot air or by lyophilization. .
  • the dried extract thus obtained is pulverized and mixed with excipients that allow compaction according to an established dosage.
  • GRAGEAS The extract of G. glauca, concerning the pharmaceutical formulation object of the present invention, can be mixed with the excipients that allow the proper drying process of the extract either by a spray drying process with hot air or by lyophilization. .
  • the dry extract thus obtained is pulverized and mixed with excipients that require compaction according to the established dosage.
  • Dragees can have an enteric layer.
  • the plant material referred to in this invention was obtained from seeds of G. glauca.
  • the seeds germinate at room temperature and humidity.
  • the preparation of the dry extract of G. glauca comprises the steps: a) Drying of the plant material, b) Grinding, c) Deceration, d) Hydroalcoholic extraction, e) Partition in ethyl acetate: water and, f) Evaporation of solvents until the product is dry.
  • the plant material of G. glauca is crushed in a blade mill with 4 to 12 mm mesh, preferably using the 8 mm mesh.
  • Deceration i) 10 to 30 kg of crushed plant material of G. glauca (particle size 4 to 12 mm mesh, preferably 8 mm mesh) are introduced into a 300 liter tank, and the plant material is covered with 7 at 10 liters per kg of plant material, preferably 7.5 liters per kg with a mixture of hexane: ethyl acetate solvents in a proportion ranging from 100 to 60%: 0 to 40%, preferably 70% hexane and 30% of ethyl acetate, at a temperature between 20 and 40 ° C, preferably 25 ° C for 24 hours.
  • the solvent mixture is recovered in a rotary evaporator, with a 20-liter ball flask, maintaining the bath temperature in a range of 35 to 55 0 C preferably 45 0 C, with the application of vacuum at a pressure between 240 and 335 mbar, preferably 310 mbar.
  • the mixture of recovered solvents is used again to repeat the depreciation of the plant material.
  • the operation is performed three times. Decent plant material
  • the resulting dispersion is placed on absorbent paper to allow for evaporation, the removal of the remains of the solvent mixture that was used in the decentration.
  • the filter is prepared with a diatomaceous earth suspension, known as Celite 504 (filter aid). Said suspension is prepared with 200 gr of the filter aid and suspended in 5 liters of the solvent system to be used. Subsequently, it is filtered using a pressure of 0.2 kg / cm 2 . The filter dries with a stream of pressurized air until there is no liquid in the filter outlet.
  • Celite 504 filter aid
  • the filtered extract is concentrated on a rotary evaporator with a 20-liter ball flask, maintaining the bath temperature in a range of 45 to 65 ° C, preferably 52 ° C with the application of vacuum at a pressure between 175 and 70 mbar , preferably 120 mbar and gradually reducing up to 70 mbar, until an aqueous suspension with an ethanol percentage of less than 10% is obtained.
  • the mixture of recovered solvents is again used to repeat the maceration of the plant material. This stage is done three times.
  • the lyophilization cycle is carried out for 36 hours under the following conditions: 4 hours with a vacuum of 1050 mbar at -45 0 C with a condenser temperature of -52 0 C, 14 hours with a vacuum of 30 mbar at -15 ° C, 14 hours with a vacuum of 30 mbar at 0 o C and, 4 hours with a vacuum of 30 mbar at 20 ° C. Finally, the extract is pulverized.
  • Phytochemical characterization of the dry extract of & glauca For the phytochemical characterization of the dry extract of G. glauca, object of the invention with the quantification of the active substances (galphiminas), a specific high-performance liquid chromatography (HPLC) protocol has been designed . Said protocol is carried out in a HPLC equipment (Waters) connected to a Waters 2695 separation module and a Waters 2996 diode array detector. This chromatography equipment is controlled with a data capture computation program (Empower Pro, Waters). The experimental conditions under which the phytochemical characterization of the dry extract of G.
  • HPLC high-performance liquid chromatography
  • galphimines are: reverse phase column (Alltima HP C18 HL 3u), the mobile phase consists of an isocratic acetonitrile system: water (35: 65), flow of 1.7 ml / min, with a total time of 20 min.
  • Galphimins A, B and E previously isolated in our laboratory and whose identity was corroborated by comparison with the spectroscopic data reported are used as reference standards for determining the concentration of active compounds.
  • the reference galphimins and the extract object of the invention are dissolved in HPLC grade methanol and injected (50 ⁇ l). Reference galphimines are injected at concentrations of 50, 100, 200 and 400 ⁇ g / ml.
  • the extract object of the invention is analyzed at a concentration of 3 mg / ml. Each sample is run in triplicate. The chromatographic profile is analyzed in a wavelength range between 200 and 400 nm, setting the reading to 220 nm. The calibration curve is obtained by measuring the area under the curve (i?
  • extract object of the invention has a higher concentration of Galphimine-B, up to 50 times more than the aqueous extract, and almost 3 times more concentration of said galphimine than methanolic and ethanolic extracts.
  • the extract object of the invention has a concentration of Galphimine-E greater than the aqueous extract of up to 45 times and 3 and 2 times higher than the methanolic and ethanolic extracts, respectively.
  • the extract object of the invention has a concentration of Galphimine-A of up to 28 times higher with respect to the aqueous extract and 3 and 2 times more than the ethanol and methanol extracts, respectively.
  • the dry extract of G. glauca object of the invention referred to in examples 2 and 3 of the present application is administered orally in male mice, strain ICR, with 30-35 g weight, at a dose of 100 mg / kg, for three occasions: at 24, 18 and 1 hour before measurement.
  • the anxiolytic effect of this extract shows an improvement with respect to the anxiolytic effect produced by other extracts obtained from the same plant previously used and disseminated (Herrera-Ruiz M, Jiménez-Ferrer JE, DE Lima TCM, Aviles-Montes D, Pérez-Garcia D , González-Cortázar M, Tortoriello J.
  • glauca have considerably lower values of anxiolytic activity, with respect to the extract object of the invention (Ext inv).
  • Data are presented as percentage of entries to open arms (D) and percentage of time over open arms (B). It is used as a diazepam control (DZP) administered at 1 mg / kg ip and as a 1% carboxymethyl cellulose (eme) vehicle.
  • DZP diazepam control
  • the data analysis is carried out by ANOVA and it is determined that the dry extract, object of the invention and the DZP show significant differences with respect to the vehicle (p ⁇ 0.05) with a Dunnet post-hoc test. While the aqueous extract (Aq) and the hydroalcoholic extract (HAq) showed no differences with the vehicle.
  • FIG. 3 shows the results of the evaluation of the aqueous (Aq), hydroalcoholic (HAq) and dry extracts object of the invention (Ext inv) extracts.
  • the data shown are the total number of crosses ( ⁇ ) and number of times of stretching (u).
  • the total number of crosses refers to the movement of animals from one quadrant to another in the open field device.
  • the number of times of stretching refers to the incorporations of the animals in the hindquarters (lifts on 2 legs).
  • Statistical analysis showed no significant difference between control and extract treatments when compared to the vehicle. Therefore, the results show that the dry extract object of the invention does not affect the spontaneous motor activity of the experimental animals.
  • excipients are added in accordance with the following percentages: lactose in a concentration between 12 and 20% solids in solution, preferably 16%; magnesium sterate in a concentration between 1 and 4% solids in solution, preferably 2.5%; surgical talc in a concentration between 0.1 and 1.2% solids in solution preferably at 0.5% and caboxil ® in a concentration between 0.2 and 1.8% solids in solution preferably at 0.8%.
  • the extract is placed in a powder mixer with 304 stainless steel tub, with a nominal capacity of 99 liters, and mixed vigorously until a homogeneous product is obtained.
  • the extract proceeds to be packed in capsules with a capacity of 250 mg.
  • Each capsule shall provide at least the following amounts of active substance: 0.35 mg of Galphimina-B (G-B), 0.34 mg of Galphimina-E (GE) and 0.11 mg of Galphimina-A (GA). ”
  • G-B Galphimina-B
  • GE Galphimina-E
  • GA Galphimina-A
  • These doses are standardized for in accordance with previous studies of the clinical study of the aqueous extract of G. glauca and are administered orally 1 or 2 times a day for an appropriate period of time to observe the anxiolytic effect, which is at least 4 continuous weeks (Herrera- Arellano A, Jiménez-Ferrer E, Zamilpa A, Morales- Valdéz M, Garc ⁇ a-Valencia Marie E, Tortoriello J. Efficacy and Tolerability of a standardized herbal product firom Galphimia glauca on generalized

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne une formulation pharmaceutique destinée au traitement de l'anxiété qui comprend un extrait sec de Galphimia glauca, dans lequel les agents actifs sont constitués par les composés appelés galphimines A, B et E. L'invention se rapporte aussi à un procédé d'obtention de l'extrait précité qui permet d'augmenter de manière notable sa concentration en principes actifs (jusqu'à 50 fois supérieure en comparaison avec les procédés de l'état antérieur de la technique) et, par conséquent, de renforcer l'effet anxiolytique de l'extrait, autorisant l'adoption de présentations pharmaceutiques, capsules ou dragées, plus petites que celles de l'état antérieur de la technique, plus efficaces et plus accessibles pour les patients. La formulation pharmaceutique précitée produit un effet anxiolytique supérieur à celui des extraits selon l'état antérieur de la technique,et sans les effets secondaires des substances pharmaceutiques actuellement utilisées dans les traitements contre l'anxiété.
PCT/MX2007/000135 2007-11-12 2007-11-12 Procédé d'obtention d'un extrait sec de galphimia glauca, compositions pharmaceutiques comprenant ledit extrait et utilisation des compositions dans le traitement contre l'anxiété Ceased WO2009064151A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/MX2007/000135 WO2009064151A1 (fr) 2007-11-12 2007-11-12 Procédé d'obtention d'un extrait sec de galphimia glauca, compositions pharmaceutiques comprenant ledit extrait et utilisation des compositions dans le traitement contre l'anxiété
MX2009007792A MX2009007792A (es) 2007-11-12 2009-07-22 Metodo para obtener un extracto seco de galphimia glauca, composiciones farmaceuticas que comprenden dicho extracto y uso de las composiciones para el tratamiento de la ansiedad.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MX2007/000135 WO2009064151A1 (fr) 2007-11-12 2007-11-12 Procédé d'obtention d'un extrait sec de galphimia glauca, compositions pharmaceutiques comprenant ledit extrait et utilisation des compositions dans le traitement contre l'anxiété

Publications (1)

Publication Number Publication Date
WO2009064151A1 true WO2009064151A1 (fr) 2009-05-22

Family

ID=40638911

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/MX2007/000135 Ceased WO2009064151A1 (fr) 2007-11-12 2007-11-12 Procédé d'obtention d'un extrait sec de galphimia glauca, compositions pharmaceutiques comprenant ledit extrait et utilisation des compositions dans le traitement contre l'anxiété

Country Status (1)

Country Link
WO (1) WO2009064151A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11220653B2 (en) * 2019-08-13 2022-01-11 Hang Yao Photocatalysis extraction method for enriching cannabidiol from the wild hemps

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2119534T3 (es) * 1995-07-10 1998-10-01 Plantamed Arzneimittel Gmbh Procedimiento para la fabricacion de preparaciones farmaceuticas con un contenido mas alto en aceites esenciales y fenoles.
DE10112168A1 (de) * 2001-03-12 2002-10-02 Bionorica Arzneimittel Ag Trockenextrakt mit einstellbarem Gehalt an lipophilen und hydrophilen Substanzen und Verfahren zur Herstellung desselben

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2119534T3 (es) * 1995-07-10 1998-10-01 Plantamed Arzneimittel Gmbh Procedimiento para la fabricacion de preparaciones farmaceuticas con un contenido mas alto en aceites esenciales y fenoles.
DE10112168A1 (de) * 2001-03-12 2002-10-02 Bionorica Arzneimittel Ag Trockenextrakt mit einstellbarem Gehalt an lipophilen und hydrophilen Substanzen und Verfahren zur Herstellung desselben

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AGUILAR-SANTAMARIA, L. ET AL.: "Toxicological and cytotoxic evaluation of standardized extracts of Galphimia glauca", JOURNAL OF ETHNOPHARMACOLOGY, vol. 109, no. 1, January 2007 (2007-01-01), pages 35 - 40, XP005786331, DOI: doi:10.1016/j.jep.2006.06.013 *
HERRARA-RUIZ, M. ET AL.: "Anxiolytic effect of natural Galphimines from Galphimia glauca and their chemical derivatives", JOURNAL OF NATURAL PRODUCTS, vol. 69, no. 1, 2006, pages 59 - 61 *
HERRERA-ARELLANO, A. ET AL.: "Efficacy and tolerability of a standardized herbal product from Galphimia glauca on generalized anxiety disorder. A. Randomized, double-blind clinical trial controlled with Lorazepam", PLANTA MEDICA, vol. 73, no. 8, July 2007 (2007-07-01), pages 713 - 717 *
HERRERA-RUIZ, M. ET AL.: "Anxiolytic and antidepressant-like activity of a standardized extract from Galphimia glauca", PHYTOMEDICINE, vol. 13, no. 1 - 2, 2006, pages 23 - 28, XP028022085, DOI: doi:10.1016/j.phymed.2005.03.003 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11220653B2 (en) * 2019-08-13 2022-01-11 Hang Yao Photocatalysis extraction method for enriching cannabidiol from the wild hemps

Similar Documents

Publication Publication Date Title
JP6091651B2 (ja) 頭痛治療用医薬組成物、及びその調製法
CN111787909B (zh) 包含小檗碱的组合物
AU2004200624A1 (en) Medicinal preparation containing phenylethanoid glycosides extracted from herbaceous plant, cistanche tubulosa (schenk.) wight, process of making the same, and uses of the same
CA2485389A1 (fr) Preparations utilisees pour le traitement de l'impuissance chez l'homme et chez la femme
TWI654987B (zh) 用於治療睡眠失調之纈草根萃取物和薰衣草油的組合
WO2008145064A1 (fr) Procédé d'obtention d'un extrait contenant du séquoyitol à partir d'une espèce du genre trifolium, de soja et de ginkgo biloba, et utilisation de celui-ci
ES2886534T3 (es) Una composición para el tratamiento de la neuropatía, un procedimiento y un método de tratamiento de la misma
CN106074588A (zh) 长柱重楼单体皂苷组合及其药物组合物和其在制药中的应用
CN105456311A (zh) 一种用于防治乳腺癌、肝癌的沙棘提取物及其制备方法和其应用
CN101167787A (zh) 抑制血管生成的合欢属植物提取物的组合物及其制备和应用
CN101254217A (zh) 一种红豆杉树可再生部分的提取物的制备方法及该提取物在制备口服抗癌药物中的应用
KR20070026329A (ko) 우울증 치료를 위한 선인장 식물체 일부 및／또는 그추출물의 용도
WO2009100587A1 (fr) Composition de médicament pour le traitement et la prévention d'un accident ischémique cérébral et ses procédés de préparation
WO2009064151A1 (fr) Procédé d'obtention d'un extrait sec de galphimia glauca, compositions pharmaceutiques comprenant ledit extrait et utilisation des compositions dans le traitement contre l'anxiété
WO2006063515A1 (fr) Utilisation de radix sanguisorbae et de son extrait pour la preparation d’un medicament visant a accroitre la numeration erythrocytaire et le taux d’hemoglobine
TWI389701B (zh) 沉香屬果殼之萃取物及其於治療癌症之用途
JP7361903B2 (ja) 芫花、威霊仙、及び天麻の複合生薬抽出物を含む神経変性疾患の予防または治療用組成物
CN103446280A (zh) 一种三七提取物、川芎提取物、红花提取物、葛根提取物与山楂提取物的组合药物及其制剂、应用
JP6444688B2 (ja) むくみ抑制または改善剤
CN105796637A (zh) 一种抗乳腺癌的中药组合物及其制备方法与应用
HUE033992T2 (hu) Körömvirág (calendula) kivonatainak alkalmazása kognitív és mentális funkciók zavarainak és károsodásainak kezelésére és megelõzésére
CN110448622B (zh) 治疗热性感冒的药物及其制备方法和应用
CN114053323B (zh) 一种防治抑郁且消除抗抑郁药物致高泌乳素血症的药物平卧菊三七制剂及其制备方法和应用
CN100584357C (zh) 含有冰片、麝香的药物组合物
CN103285087A (zh) 啤酒花有效部位用于制备预防及改善焦虑症及其临床症状的药物的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07851835

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/007792

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07851835

Country of ref document: EP

Kind code of ref document: A1